Market Overview

Baxter Parenteral Nutrition Study Describes Lack of Quality Evidence That Fish Lipid Emulsions Significantly Improve Clinical Outcomes

  • Baxter publishes largest qualitative review of 34 global studies
    about efficacy of different lipid emulsions for parenteral nutrition

Baxter International Inc. (NYSE:BAX), a global leader in nutrition
therapy, announced today the publication of "Fish
Oil Containing Lipid Emulsions in Adult Parenteral Nutrition: A Review
of the Evidence
" in the Journal of Parenteral and Enteral
. The findings from this review of the clinical literature
do not demonstrate a significant improvement in any of the clinical
outcomes assessed for patients who received fish oil containing
intravenous lipid emulsions (IVLEs) versus other IVLEs during parenteral
nutrition (PN) therapy. The publication represents the largest
qualitative review of available clinical studies, the majority of which
have reported little difference in mortality, length of hospitalization,
ICU-based clinical outcomes, post-operative complications, or rates of
infection and sepsis.

Noting the variable quality of the relevant clinical research and
literature, the publication underscores the need for high quality
research into IVLEs.

"Lipid emulsions are an important component of PN therapy, yet these
findings may explain why the recently published joint guidelines from
the Society of Critical Care Medicine and the American Society for
Parenteral and Enteral Nutrition do not provide recommendations
regarding the use of one IVLE over another," said Alessandro
Pontes-Arruda, MD, Medical Director, Baxter. "This is why Baxter is
committed to supporting qualitative research to assist healthcare
providers in making well-informed clinical decisions about parenteral
nutrition therapy."

PN is an intravenous (IV) therapy, which may include a balance of
protein, carbohydrates, lipids, electrolytes, vitamins and trace
elements for patients who require supplemental nutrition care, or cannot
ingest food orally or enterally (tube-fed). IVLEs are a vital part of
PN, as a source of essential fatty acids and as an energy source.

"Fish Oil Containing Lipid Emulsions in Adult Parenteral Nutrition: A
Review of the Evidence," includes a critical assessment of 34 recent
randomized controlled clinical trials and other clinical studies, which
encompassed more than 3,400 adult PN patients globally. Researchers used
the Cochrane Collaboration assessment method to mitigate risk of bias.1

About Baxter's Global Nutrition Business

Baxter has been assisting clinicians in treating patients' diverse
nutrient needs since the 1940s, when the company first introduced liquid
proteins in the form of amino acids. Since then, Baxter has continued to
advance PN therapy. As an example, Baxter pioneered the world's first
"triple-chamber system" internationally for IV nutrition, which provides
many of the essential ingredients of balanced nutrition – protein,
carbohydrates, lipids and electrolytes in a single container --
simplifying the preparation of PN for patients.

Today, Baxter provides one of the broadest PN portfolios globally, which
includes premix IV solutions, vitamins and lipids, as well as pharmacy
workflow management, labeling and compounding technology. Baxter's lipid
emulsions are available globally in multi-chamber, ready-to-use
solutions, and single solution bags that can be added to a compounded or
premixed bag to ensure clinicians can prescribe the best well-balanced
therapy for their individual patients.

About Baxter

Baxter provides a broad portfolio of essential renal and hospital
products, including home, acute and in-center dialysis; sterile IV
solutions; infusion systems and devices; parenteral nutrition; surgery
products and anesthetics; and pharmacy automation, software and
services. The company's global footprint and the critical nature of its
products and services play a key role in expanding access to healthcare
in emerging and developed countries. Baxter's employees worldwide are
building upon the company's rich heritage of medical breakthroughs to
advance the next generation of healthcare innovations that enable
patient care.

Baxter is a registered trademark of Baxter International Inc.

1 Higgins JPT et al. Cochrane Handbook for Systematic Reviews
of Interventions Version 510. Chapter 8: assessing the risk of bias in
included studies. In: Higgins JPT, Deeks JJ, Altman DG, eds. Cochrane
Handbook for Systematic Reviews of Interventions Version 510 [updated
March 2011]. Oxford, UK: Cochrane Collaboration; 2011

View Comments and Join the Discussion!